In nearly 20 years, aside from cholinesterase inhibitors, memantine is the only drug approved for the treatment of Alzheimer's disease (AD). Memantine is an uncompetitive N-methyl-D-aspartate ...

Another earlier memantine trial – the Benefit and Efficacy in Severely Demented patients during Treatment with Memantine (M-Best or 9403) study – enrolled participants with moderately severe ...

Objective To investigate the effect on survival of treatment with memantine in patients with dementia with Lewy bodies (DLB) and Parkinson's disease with dementia (PDD). Methods 75 patients with DLB ...

抑郁症是一种常见的精神障碍。单胺类抗抑郁药是一线治疗方案，但其对部分患者仍然无效。协同调节神经炎症和神经可塑性是治疗抑郁症的主要策略。有鉴于此，四川大学高会乐教授开发了一种靶向炎症的小胶质细胞仿生系统PDA-Mem@M，并将其用于治疗抑郁症。

The growth of the Alzheimer's Disease Therapeutics Market is directly influenced by the increasing prevalence of Alzheimer's disease globally. The hi ...

JPMorgan upgraded Amneal Pharmaceuticals (AMRX) to Overweight from Neutral with a price target of $12, up from $9. The firm cites the Crexont ...

Today, as part of a national initiative funded by The John A. Hartford Foundation (JAHF), the national, independent nonprofit ...

Receiving routine vaccinations against common infections like tetanus, shingles, and pneumonia may offer an unexpected ...

The company announced today that it has launched memantine/donepezil extended-release capsules for Alzheimer's-related dementia, with an exclusive 180-day marketing period. Additionally ...

Today, as part of a national initiative funded by The John A. Hartford Foundation (JAHF), the national, independent nonprofit FAIR Health launched a new shared decision-making tool for Alzheimer's ...

Good morning, everyone, and welcome to the Anavex Life Sciences Fiscal 2025 First Quarter Conference Call. My name is Clint ...

After hours: February 21 at 6:29:36 PM EST Loading Chart for AMRX ...